ArticleJournal of cancer research and clinical oncology2026
OLFM4 orchestrates the immunosuppressive microenvironment and drives gallbladder cancer progression.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeGallbladder cancer (GBC) is the most common biliary tract malignancy, characterized by complex microenvironment and poor prognosis. Olfactomedin-4 (OLFM4) has been identified as a key regulator of GBC progression. This study aims to comprehensively elucidate the molecular profiling, tumor microenvironment (TME) and underlying mechanisms through which OLFM4 drives GBC progression.
methodsSingle-cell RNA sequencing (scRNA-seq) was performed on tumor tissues and adjacent non-tumor tissues (ANT) from clinical GBC samples. We analyzed scRNA-seq data to characterize the landscape of heterogeneous TME and intricate intercellular communication networks of the single cells within GBC. Findings were validated through in vitro experiments.
resultsCompared with ANT, GBC exhibited a distinct remodeling of the tumor microenvironment. Specifically, epithelial cells were markedly enriched in GBC (18.2% vs. 11.6% in ANT), accompanied by a pronounced reduction in endothelial cells (2.4% vs. 9.7%). In parallel, myeloid cells decreased from 16.8% in ANT to 11.5% in GBC, while fibroblasts remained comparably abundant in both conditions (21.1%). Within the OLFM4+epithelium, there was a significant enrichment of genes and pathways related to malignant progression, including signatures driving cell proliferation, stemness maintenance (WNT/β-catenin), and metastasis, as well as crucial molecules involved in TME remodeling (SPP1, TGF-β). Pseudotemporal trajectory analysis revealed an upregulation of OLFM4 expression correlating with disease progression, suggesting its close association with malignant transition. Cell-cell communication analysis identified OLFM4+epithelial cells as central signaling hubs, primarily communicating with stromal and immune cells via the SPP1-CD44 and SPP1-Integrin axes. Importantly, OLFM4 knockdown inhibited cell proliferation, migration, invasion, and gemcitabine chemoresistance in vitro, underscoring its central role in GBC progression.
conclusionThese findings offer a comprehensive insight into the atlas of molecular signatures and TME within GBC, identifying OLFM4 as a potential biomarker and therapeutic target for GBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.